MDMB-BINACA

MDMB-BINACA
Identifiers
	IUPAC name methyl (2S)-2-[(1-butylindazole-3-carbonyl)amino]-3,3-dimethylbutanoate;
PubChem CID	165361538;
ChemSpider	79413388;
UNII	AN7ERQ8YHM;
Chemical and physical data
Formula	C19H27N3O3
Molar mass	345.443 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCN1C2=CC=CC=C2C(=N1)C(=O)N[C@H](C(=O)OC)C(C)(C)C;
	InChI InChI=1S/C19H27N3O3/c1-6-7-12-22-14-11-9-8-10-13(14)15(21-22)17(23)20-16(18(24)25-5)19(2,3)4/h8-11,16H,6-7,12H2,1-5H3,(H,20,23)/t16-/m1/s1; Key:YHAWFWPNIXPRDT-MRXNPFEDSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

MDMB-BINACA (MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as ADB-BUTINACA and MDMB-5'Br-BUTINACA, and is believed to have similar effects.^[1]

References

^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[1] "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.

[1]

See also

References